← Back to Analyst Consensus 
ODTX Buy
Odyssey Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | UBS | initiate | — → Buy | — | 54% |
| Oct 9, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Aug 27, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Aug 7, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Jun 18, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Jun 2, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Jun 2, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| Jun 2, 2026 | Wedbush | initiate | — → Outperform | — | 58% |
| Jun 2, 2026 | JP Morgan | initiate | — → Overweight | — | 55% |
| Jun 2, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
Price Target Trend
Jun 6, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days